<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040312</url>
  </required_header>
  <id_info>
    <org_study_id>TOP009-062</org_study_id>
    <secondary_id>090946</secondary_id>
    <nct_id>NCT01040312</nct_id>
  </id_info>
  <brief_title>An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors</brief_title>
  <official_title>A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the correlation between UGT1A1 genotypes and the
      safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for
      patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2009</start_date>
  <completion_date type="Actual">September 2, 2015</completion_date>
  <primary_completion_date type="Actual">September 29, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with UGT1A1 Genotype with Severe Toxicities Induced by CPT-11 with Platinum Analogues</measure>
    <time_frame>within 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate of Participants with UGT1A1 genotype to CPT-11 with Platinum Analogues</measure>
    <time_frame>within 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response to CPT-11 with Platinum Analogues in Participants with UGT1A1 Genotype</measure>
    <time_frame>within 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">321</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Gastric Cancer (Inoperable and Recurrent)</condition>
  <arm_group>
    <arm_group_label>UGT1A1 genotyped patients</arm_group_label>
    <description>UGT1A1 genotyped patients receive CPT-11 with platinum analogues</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11</intervention_name>
    <description>CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.</description>
    <arm_group_label>UGT1A1 genotyped patients</arm_group_label>
    <other_name>Camptosar</other_name>
    <other_name>Topotecin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum analogues</intervention_name>
    <description>Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.</description>
    <arm_group_label>UGT1A1 genotyped patients</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>Carboplatin</other_name>
    <other_name>Nedaplatin</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      white cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in Japan with small cell lung cancer, non-small cell lung cancer, cervical cancer,
        ovarian cancer and/or gastric cancer treated with CPT-11 plus platinum analogues
        (cisplatin, carboplatin and nedaplatin) in clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian
             cancer and/or gastric cancer

          -  Has UGT1A1 genotype *1/*6, *1/*28, *6/*6, *28/*28 and *6/*28

          -  Is receiving CPT-11 plus platinum analogue (cisplatin, carboplatin and nedaplatin)
             regimens (with or without molecular targeted agents)

        Exclusion Criteria:

          -  Has contraindication for CPT-11

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 3-4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, National Defense Medical College Hospital</name>
      <address>
        <city>Tokorozawa</city>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UGT1A1, irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

